Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00793819 · ClinicalTrials.gov registry record · Phase 2
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
A Phase 2 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
NCT00793819 is a Phase 2 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 215 participants.
The verdict
NCT00793819, a Phase 2 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
Study Summary
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
Interventions
- DRUG silodosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00793819
The ClinicalTrials.gov registry entry for NCT00793819 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which silodosin is the first listed.
NCT00793819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00793819 about?
NCT00793819 is a clinical study titled "A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia". Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
What is the current status of trial NCT00793819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2009-01. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00793819?
The interventions under investigation include: silodosin (DRUG).
Who is sponsoring clinical trial NCT00793819?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.